


## Taurocholic acid sodium salt hydrate

<b>Cat. No.:</b>	HY-B1131
<b>CAS No.:</b>	345909-26-4
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>46</sub> NNaO <sub>8</sub> S
<b>Molecular Weight:</b>	556
<b>Target:</b>	Endogenous Metabolite
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (224.82 mM; ultrasonic and warming and heat to 60°C)  
 H<sub>2</sub>O : ≥ 100 mg/mL (179.86 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.7986 mL	8.9928 mL	17.9856 mL
	5 mM	0.3597 mL	1.7986 mL	3.5971 mL
	10 mM	0.1799 mL	0.8993 mL	1.7986 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 100 mg/mL (179.86 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Taurocholic acid sodium salt hydrate (Sodium taurocholate hydrate) is a bile acid involved in the emulsification of fats.

#### IC<sub>50</sub> & Target

Human Endogenous Metabolite	Microbial Metabolite
-----------------------------	----------------------

## In Vivo

Taurocholic acid (sodium salt hydrate) can be used in animal modeling to construct animal models of pancreatitis.

The bile acid Taurocholic acid sodium salt hydrate (Sodium taurocholate hydrate) exerts permeation enhancing effects in vivo<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Research (Wash D C). 2022 Nov 2;2022:9784081.
- Antiviral Res. 2019 Jun 27;169:104544.
- Biomolecules. 2022, 12(8), 1063.
- FASEB J. 2022 May;36(5):e22305.
- RSC Adv. 2018 8:8469-8483.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Mooranian A, et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015 Oct;5(5):511-22.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA